Vanguard Group’s Armata Pharmaceuticals ARMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $2.25M | Buy |
357,649
+60,611
| +20% | +$332K | ﹤0.01% | 3524 |
|
|
2025
Q3 | $885K | Buy |
297,038
+36,965
| +14% | +$95.6K | ﹤0.01% | 3818 |
|
|
2025
Q2 | $494K | Hold |
260,073
| – | – | ﹤0.01% | 3921 |
|
|
2025
Q1 | $380K | Buy |
260,073
+25,954
| +11% | +$51.7K | ﹤0.01% | 3940 |
|
|
2024
Q4 | $433K | Buy |
234,119
+8,832
| +4% | +$19.9K | ﹤0.01% | 3977 |
|
|
2024
Q3 | $534K | Buy |
225,287
+19,534
| +9% | +$49.9K | ﹤0.01% | 3959 |
|
|
2024
Q2 | $566K | Buy |
205,753
+46,544
| +29% | +$133K | ﹤0.01% | 3962 |
|
|
2024
Q1 | $665K | Buy |
159,209
+14,131
| +10% | +$51.2K | ﹤0.01% | 3943 |
|
|
2023
Q4 | $470K | Buy |
145,078
+54,109
| +59% | +$128K | ﹤0.01% | 4048 |
|
|
2023
Q3 | $273K | Buy |
90,969
+31,079
| +52% | +$83.3K | ﹤0.01% | 4200 |
|
|
2023
Q2 | $68.3K | Buy |
59,890
+2,708
| +5% | +$3.94K | ﹤0.01% | 4425 |
|
|
2023
Q1 | $95.5K | Buy |
57,182
+13,387
| +31% | +$31.1K | ﹤0.01% | 4411 |
|
|
2022
Q4 | $54.3K | Sell |
43,795
-243,555
| -85% | -$634K | ﹤0.01% | 4438 |
|
|
2022
Q3 | $1.21M | Buy |
287,350
+14,200
| +5% | +$57.2K | ﹤0.01% | 3940 |
|
|
2022
Q2 | $1.06M | Hold |
273,150
| – | – | ﹤0.01% | 4067 |
|
|
2022
Q1 | $1.33M | Buy |
273,150
+10,400
| +4% | +$53.3K | ﹤0.01% | 4120 |
|
|
2021
Q4 | $1.44M | Buy |
262,750
+94,092
| +56% | +$393K | ﹤0.01% | 4153 |
|
|
2021
Q3 | $610K | Buy |
168,658
+1,280
| +0.8% | +$4.87K | ﹤0.01% | 4351 |
|
|
2021
Q2 | $665K | Buy |
167,378
+91,782
| +121% | +$386K | ﹤0.01% | 4220 |
|
|
2021
Q1 | $362K | Buy |
75,596
+60,446
| +399% | +$297K | ﹤0.01% | 4180 |
|
|
2020
Q4 | $45K | Hold |
15,150
| – | – | ﹤0.01% | 4186 |
|
|
2020
Q3 | $48K | Hold |
15,150
| – | – | ﹤0.01% | 4067 |
|
|
2020
Q2 | $59K | Hold |
15,150
| – | – | ﹤0.01% | 4024 |
|
|
2020
Q1 | $47K | Hold |
15,150
| – | – | ﹤0.01% | 4003 |
|
|
2019
Q4 | $49K | Hold |
15,150
| – | – | ﹤0.01% | 4046 |
|
|
2019
Q3 | $56K | Sell |
15,150
-1
| -0% | -$4 | ﹤0.01% | 4074 |
|
|
2019
Q2 | $61K | Hold |
15,151
| – | – | ﹤0.01% | 4091 |
|
|
2019
Q1 | $64K | Hold |
15,151
| – | – | ﹤0.01% | 4045 |
|
|
2018
Q4 | $44K | Sell |
15,151
-3,236
| -18% | -$15.8K | ﹤0.01% | 4080 |
|
|
2018
Q3 | $260K | Buy |
18,387
+3,236
| +21% | +$47.2K | ﹤0.01% | 3967 |
|
|
2018
Q2 | $240K | Buy |
15,151
+8,126
| +116% | +$132K | ﹤0.01% | 3950 |
|
|
2018
Q1 | $107K | Hold |
7,025
| – | – | ﹤0.01% | 4024 |
|
|
2017
Q4 | $99K | Buy |
7,025
+4,925
| +235% | +$72.7K | ﹤0.01% | 3994 |
|
|
2017
Q3 | $27K | Buy |
+2,100
| New | +$26.9K | ﹤0.01% | 4049 |
|
|
2017
Q2 | – | Sell |
-1,464
| Closed | -$88K | – | 4075 |
|
|
2017
Q1 | $88K | Buy |
1,464
+325
| +29% | +$22.1K | ﹤0.01% | 3994 |
|
|
2016
Q4 | $70K | Buy |
1,139
+465
| +69% | +$57.8K | ﹤0.01% | 4003 |
|
|
2016
Q3 | $141K | Buy |
674
+178
| +36% | +$41K | ﹤0.01% | 3949 |
|
|
2016
Q2 | $107K | Hold |
496
| – | – | ﹤0.01% | 4018 |
|
|
2016
Q1 | $275K | Buy |
496
+6
| +1% | +$3.08K | ﹤0.01% | 3900 |
|
|
2015
Q4 | $274K | Buy |
+490
| New | +$375K | ﹤0.01% | 3961 |
|
Other funds holding ARMP
6CM
BCM
SWM
GWM
Vanguard Group's ARMP Position: Q4 2025 in Review
Vanguard Group increased its Armata Pharmaceuticals (ARMP) stake by 20% in Q4 2025, buying an estimated $332K and bringing the position to 357,649 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #3524.
Vanguard Group first reported a position in ARMP in Q4 2015 and has held it in 40 quarters since. 36 funds tracked by Wall St. Rank hold ARMP as of Q4 2025.
- Vanguard Group held 357,649 shares of Armata Pharmaceuticals worth $2.25M as of Q4 2025.
- Vanguard Group bought 60,611 Armata Pharmaceuticals shares in Q4 2025, an estimated $332K.
- Armata Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3524 holding.
- Vanguard Group first reported a position in Armata Pharmaceuticals in Q4 2015 and has held it in 40 quarters since.
- 36 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.